Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ivor R. Elrifi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Beta
- 0.45
- Country
- GB
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -15.55
Financials
Revenue
$0.00-100.0%Net Income
$-12.80MEBITDA
$-12.18MFree Cash Flow
$-6.04MEPS (diluted)
$-0.22Shares Outstanding (diluted)
59.47M+468554.4%Operating Expenses
$12.18MCash & Debt
$4.01MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-18.43M | $-0.32 |
| 2024 | $0.00 | $-11.86M | $-0.22 |
| 2023 | $0.00 | $-22.36M | $-0.42 |
| 2022 | $0.00 | $-18.92M | $-0.36 |
| 2021 | $0.00 | $-31.59M | $-0.64 |
| 2020 | $0.00 | $-35.54M | $-0.74 |
| 2019 | $0.00 | $-9.36M | $-0.14 |
| 2018 | $0.00 | $-7.98M | $-0.12 |
| 2017 | $0.00 | $-6.77M | $-0.12 |
| 2016 | $0.00 | $-7.21M | $-0.14 |
| 2015 | $0.00 | $-8.63M | $-0.18 |
| 2014 | $0.00 | $-3.51M | $-0.62 |
| 2013 | $3.0K | $-280.0K | $-0.02 |
| 2012 | $0.00 | $-848.0K | $-0.94 |
Valuation
TLSAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.00%Social Signal Score
Mentions (5)
- Newsproactiveinvestors.com·10d ago·Negative
Tiziana doses first three patients in ALS trial of nasal antibody foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS). The Healey ALS MyMatch BANYAN trial is testing foralumab, a fully human anti-CD3 monoclonal antibody, delivered as a nasal spray.
View source ↗ - Newsproactiveinvestors.com·21d ago·Negative
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis patients. The planned trial will target relapsing-remitting multiple sclerosis (RRMS) patients who respond poorly to anti-CD…
View source ↗ - Newsproactiveinvestors.com·34d ago·Neutral
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and redu…
View source ↗ - Newsproactiveinvestors.com·45d ago·Neutral
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is scheduled for 4:30 pm to 6:30 pm Eastern Time during the Scientific Poster Session.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…esentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” wi…
View source ↗
Earnings
Typical surprise -35.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 18$-0.08 vs $-0.08miss
- Fri, May 1$-0.22 vs $-0.09miss
- Fri, Oct 3$-0.10 vs $-0.07miss
Estimates and results for TLSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLSA officers and directors.
- Bought
- $1.0m
- Sold
- —
5 trades
0 trades
- Elrifi Ivorbought
- Elrifi Ivorbought
- Elrifi Ivorbought
- Cerrone Gabriele Mbought
- Cerrone Gabriele Mbought
15 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TLSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.